scispace - formally typeset
N

Nicola Micale

Researcher at University of Messina

Publications -  109
Citations -  2560

Nicola Micale is an academic researcher from University of Messina. The author has contributed to research in topics: Chemistry & AMPA receptor. The author has an hindex of 26, co-authored 97 publications receiving 2133 citations. Previous affiliations of Nicola Micale include Emory University & University of Milan.

Papers
More filters
Journal ArticleDOI

Synthesis and anticonvulsant activity of novel and potent 6,7-methylenedioxyphthalazin-1(2H)-ones.

TL;DR: The synthesis of a series of novel substituted 4-aryl-6,7-methylenedioxyphthalazin-1(2H)-ones, which shows a longer lasting anticonvulsant activity against audiogenic seizures and antagonizes in vivo seizures induced by 2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)propionic acid (AMPA) and kainate (KA).
Journal ArticleDOI

Development of Peptidomimetics with a Vinyl Sulfone Warhead as Irreversible Falcipain-2 Inhibitors

TL;DR: A new class of peptidomimetic cysteine protease inhibitors based on a 1,4-benzodiazepine scaffold and on an electrophilic vinyl sulfone moiety is described, proven to be potent and selective inhibitors of falcipain-2, a cysteined protease isolated from Plasmodiumfalciparum, displaying antiplasmodial activity.
Journal ArticleDOI

Subunit-specific agonist activity at NR2A-, NR2B-, NR2C-, and NR2D-containing N-methyl-D-aspartate glutamate receptors

TL;DR: Despite high homology and conserved atomic contact residues within the agonist binding pocket of NR2A and NR2D, glutamate adopts a different binding orientation that could be exploited for the development of subunit selective agonists and competitive antagonists.
Journal ArticleDOI

Falcipain-2 inhibitors

TL;DR: This review is focused on inhibitors ofFalcipain‐2, a cysteine protease from P. falciparum, which represents one of the most promising targets for antimalarial drug design.
Journal ArticleDOI

Inhibition of rhodesain as a novel therapeutic modality for human African trypanosomiasis.

TL;DR: The main classes of rhodesain inhibitors are discussed, including peptidic, peptidomimetic, and nonpeptidic structures, emphasizing those that have exhibited an optimal match between enzymatic affinity and trypanocidal profile and those for which preclinical investigations are currently in progress.